Literature DB >> 23460636

Use of biologics in a patient with rheumatoid arthritis refractory to methotrexate.

Jasvinder A Singh1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23460636      PMCID： PMC3680558          DOI： 10.1503/cmaj.121607

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  15 in total

Review 1.  Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission.

Authors:  B Kuriya; E V Arkema; V P Bykerk; E C Keystone
Journal:  Ann Rheum Dis       Date:  2010-04-26       Impact factor: 19.103

Review 2.  2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Authors:  Jasvinder A Singh; Daniel E Furst; Aseem Bharat; Jeffrey R Curtis; Arthur F Kavanaugh; Joel M Kremer; Larry W Moreland; James O'Dell; Kevin L Winthrop; Timothy Beukelman; S Louis Bridges; W Winn Chatham; Harold E Paulus; Maria Suarez-Almazor; Claire Bombardier; Maxime Dougados; Dinesh Khanna; Charles M King; Amye L Leong; Eric L Matteson; John T Schousboe; Eileen Moynihan; Karen S Kolba; Archana Jain; Elizabeth R Volkmann; Harsh Agrawal; Sangmee Bae; Amy S Mudano; Nivedita M Patkar; Kenneth G Saag
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

3.  Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis.

Authors:  Wassila Amari; Angelique L Zeringue; Jay R McDonald; Liron Caplan; Seth A Eisen; Prabha Ranganathan
Journal:  Rheumatology (Oxford)       Date:  2011-03-16       Impact factor: 7.580

4.  Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2000-06-09

Review 5.  Adverse effects of biologics: a network meta-analysis and Cochrane overview.

Authors:  Jasvinder A Singh; George A Wells; Robin Christensen; Elizabeth Tanjong Ghogomu; Lara Maxwell; John K Macdonald; Graziella Filippini; Nicole Skoetz; Damian Francis; Luciane C Lopes; Gordon H Guyatt; Jochen Schmitt; Loredana La Mantia; Tobias Weberschock; Juliana F Roos; Hendrik Siebert; Sarah Hershan; Michael Pt Lunn; Peter Tugwell; Rachelle Buchbinder
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

6.  Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Rheum       Date:  2007-09

Review 7.  A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis.

Authors:  Margaret H Y Ma; Gabrielle H Kingsley; David L Scott
Journal:  Rheumatology (Oxford)       Date:  2009-11-16       Impact factor: 7.580

8.  Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis.

Authors:  Maria A Lopez-Olivo; Jean H Tayar; Juan A Martinez-Lopez; Eduardo N Pollono; Jose Polo Cueto; M Rosa Gonzales-Crespo; Stephanie Fulton; Maria E Suarez-Almazor
Journal:  JAMA       Date:  2012-09-05       Impact factor: 56.272

Review 9.  Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity.

Authors:  Vibeke Strand; Jasvinder A Singh
Journal:  Drugs       Date:  2010       Impact factor: 9.546

10.  Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.

Authors:  Michael E Weinblatt; Michael Schiff; Robert Valente; Désirée van der Heijde; Gustavo Citera; Cathy Zhao; Michael Maldonado; Roy Fleischmann
Journal:  Arthritis Rheum       Date:  2013-01
View more
  1 in total

1.  FM0807 decelerates experimental arthritis progression by inhibiting inflammatory responses and joint destruction via modulating NF-κB and MAPK pathways.

Authors:  Nanwen Zhang; Zhiwei Liu; Hongbin Luo; Weifang Wu; Kaimei Nie; Lin Cai; Shuangyu Tan; Xiaole Chen; Ying Huang; Jiaxing Liu; Meina Lv; Xin Zhang; Yun Fan; Yuying Lin; Shennan Ye; Yang Liu; Lixian Wu; Jianhua Xu
Journal:  Biosci Rep       Date:  2019-09-03       Impact factor: 3.840
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.